---
figid: PMC3286973__pnas.1018854108fig03
figlink: /pmc/articles/PMC3286973/figure/fig03/
number: Fig. 3
caption: Pathway diagrams can be used to predict response to therapies. (A) (Left)
  Basal breast cancer cell lines respond preferentially to the DNA-damaging agent
  cisplatin. Each boxplot represents the distribution of drug response data for basal
  (right) and non-basal (left) cell lines. (Right) Basal cell lines show enhanced
  pathway levels in a subnetwork associated with the DNA-damage response, providing
  a possible mechanism by which cisplatin acts in these cell lines. (B) (Left) ERBB2AMP
  cell lines are sensitive to the HSP90 inhibitor geldanamycin. (Right) The ERBB2–HSP90
  network is up-regulated in ERBBP2AMP cell lines. Conventions are as in . BCL6, B-cell
  CLL/lymphoma 6; CASP1, caspase 1, apoptosis-related cysteine peptidase (interleukin
  1, beta, convertase); CASP6, caspase 6, apoptosis-related cysteine peptidase; CHEK2,
  CHK2 checkpoint homolog (S. pombe); DOCK7, dedicator of cytokinesis 7; ERBB3, v-erb-b2
  erythroblastic leukemia viral oncogene homolog 3 (avian); ERBB4, v-erb-a erythroblastic
  leukemia viral oncogene homolog 4 (avian); EREG, epiregulin; FAS, Fas (TNF receptor
  superfamily, member 6); GADD45A, growth arrest and DNA-damage-inducible, alpha;
  NRG1B, neuregulin 1; NRG2, neuregulin 2; PLK3, polo-like kinase 3; TP53, tumor protein
  p53; TP63, tumor protein p63.
pmcid: PMC3286973
papertitle: Subtype and pathway specific responses to anticancer compounds in breast
  cancer.
reftext: Laura M. Heiser, et al. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2724-2729.
pmc_ranked_result_index: '17645'
pathway_score: 0.2703707
filename: pnas.1018854108fig03.jpg
figtitle: Pathway diagrams can be used to predict response to therapies
year: '2012'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3286973__pnas.1018854108fig03.html
  '@type': Dataset
  description: Pathway diagrams can be used to predict response to therapies. (A)
    (Left) Basal breast cancer cell lines respond preferentially to the DNA-damaging
    agent cisplatin. Each boxplot represents the distribution of drug response data
    for basal (right) and non-basal (left) cell lines. (Right) Basal cell lines show
    enhanced pathway levels in a subnetwork associated with the DNA-damage response,
    providing a possible mechanism by which cisplatin acts in these cell lines. (B)
    (Left) ERBB2AMP cell lines are sensitive to the HSP90 inhibitor geldanamycin.
    (Right) The ERBB2–HSP90 network is up-regulated in ERBBP2AMP cell lines. Conventions
    are as in . BCL6, B-cell CLL/lymphoma 6; CASP1, caspase 1, apoptosis-related cysteine
    peptidase (interleukin 1, beta, convertase); CASP6, caspase 6, apoptosis-related
    cysteine peptidase; CHEK2, CHK2 checkpoint homolog (S. pombe); DOCK7, dedicator
    of cytokinesis 7; ERBB3, v-erb-b2 erythroblastic leukemia viral oncogene homolog
    3 (avian); ERBB4, v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian);
    EREG, epiregulin; FAS, Fas (TNF receptor superfamily, member 6); GADD45A, growth
    arrest and DNA-damage-inducible, alpha; NRG1B, neuregulin 1; NRG2, neuregulin
    2; PLK3, polo-like kinase 3; TP53, tumor protein p53; TP63, tumor protein p63.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TP63
  - ERBB2
  - ATM
  - BCL6
  - ERBB3
  - TSPAN4
  - CHEK2
  - EREG
  - ERBB4
  - CHEK1
  - PLK3
  - TP53
  - FAS
  - CASP6
  - HSP90B1
  - TRAP1
  - HSP90AB1
  - GADD45A
  - Geldanamycin
  - Cisplatin
genes:
- word: (TP63
  symbol: TP63
  source: hgnc_symbol
  hgnc_symbol: TP63
  entrez: '8626'
- word: ERBB2/ERBB4/
  symbol: ERBB2
  source: hgnc_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: ATM
  symbol: ATM
  source: hgnc_symbol
  hgnc_symbol: ATM
  entrez: '472'
- word: BCL6
  symbol: BCL6
  source: hgnc_symbol
  hgnc_symbol: BCL6
  entrez: '604'
- word: ERBB2/ERBB3/
  symbol: ERBB3
  source: hgnc_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: ERBB3/NÁG2
  symbol: NAG-2
  source: hgnc_alias_symbol
  hgnc_symbol: TSPAN4
  entrez: '7106'
- word: CHEK2
  symbol: CHEK2
  source: hgnc_symbol
  hgnc_symbol: CHEK2
  entrez: '11200'
- word: EREG
  symbol: EREG
  source: hgnc_symbol
  hgnc_symbol: EREG
  entrez: '2069'
- word: ERBB2/ERBB4/
  symbol: ERBB4
  source: hgnc_symbol
  hgnc_symbol: ERBB4
  entrez: '2066'
- word: CHEK1
  symbol: CHEK1
  source: hgnc_symbol
  hgnc_symbol: CHEK1
  entrez: '1111'
- word: PLK3
  symbol: PLK3
  source: hgnc_symbol
  hgnc_symbol: PLK3
  entrez: '1263'
- word: TP53
  symbol: TP53
  source: hgnc_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: FAS
  symbol: FAS
  source: hgnc_symbol
  hgnc_symbol: FAS
  entrez: '355'
- word: ČASP6
  symbol: CASP6
  source: hgnc_symbol
  hgnc_symbol: CASP6
  entrez: '839'
- word: HSP90
  symbol: HSP90
  source: bioentities_symbol
  hgnc_symbol: HSP90B1
  entrez: '7184'
- word: HSP90
  symbol: HSP90
  source: bioentities_symbol
  hgnc_symbol: TRAP1
  entrez: '10131'
- word: HSP90
  symbol: HSP90
  source: bioentities_symbol
  hgnc_symbol: HSP90AB1
  entrez: '3326'
- word: GĄDD45A
  symbol: GADD45A
  source: hgnc_symbol
  hgnc_symbol: GADD45A
  entrez: '1647'
chemicals:
- word: Geldanamycin
  source: MESH
  identifier: C001277
- word: Cisplatin
  source: MESH
  identifier: D002945
diseases: []
---
